China Pharma Holdings (CPHI) Liabilities and Shareholders Equity (2010 - 2026)

China Pharma Holdings (CPHI) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $45.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 217.53% year-over-year to $45.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.7 million (up 86.01% YoY) and the FY2025 annual result came in at $31.0 million, up 108.22% from the prior year.
• Liabilities and Shareholders Equity advanced to $45.1 million in Q1 2026, from $31.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $45.1 million in Q1 2026 to a low of $13.5 million in Q3 2024.
• A 5-year average of $18.6 million and a median of $16.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slipped 21.48% — and 2026, when it soared 217.53%.
• Tracing CPHI's Liabilities and Shareholders Equity over 5 years: stood at $17.8 million in 2022, then declined by 7.39% to $16.5 million in 2023, then decreased by 9.6% to $14.9 million in 2024, then soared by 108.22% to $31.0 million in 2025, then soared by 45.63% to $45.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $45.1 million (Q1 2026), $31.0 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.